PTGX - Protagonist Therapeutics, Inc. Summary, Stock Quote and News

Market Overview

22.41 1.11 (5.19%)

Data as of Dec 05, 2020

Prev. Close 21.3
Price Open 21.29
Volume 293,513
Day's Range 21.07 - 22.41
52 Wk Range 4.47 - 24.96
50 Day Moving Avg. 21.11
PE Ratio
Shares Outstanding 38.26M
Market Cap 857.14M

Trade PTGX stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
9/18/20	HC Wainwright & Co.	Maintains	Buy	33.0
7/15/20	Jefferies	Initiates Coverage On	Buy	27.0
5/22/20	SVB Leerink	Maintains	Outperform	30.0

Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation From FDA Benzinga NewsdeskWed, 02 Dec 2020 07:01:55 -0500
Stocks That Hit 52-Week Highs On Friday Benzinga InsightsFri, 27 Nov 2020 12:27:14 -0500
The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Shanthi RexalineThu, 05 Nov 2020 07:54:15 -0500
Protagonist Therapeutics Q3 EPS $(0.21) Up From $(0.61) YoY, Sales $13.11M Up From $4.14M YoY Benzinga NewsdeskWed, 04 Nov 2020 17:09:57 -0500
Protagonist Therapeutics To Present Updated Clinical Data For Hepcidin Mimetic PTG-300 In Polycythemia Vera At The American Society For Hematology (ASH) 2020 Annual Meeting Benzinga NewsdeskWed, 04 Nov 2020 10:22:01 -0500
Protagonist Therapeutics Announces Two Additional Oral IL-23 Receptor Antagonists From Program In Collaboration With Janssen Have Been Selected For Advancement Into Clinical Development Benzinga NewsdeskThu, 29 Oct 2020 16:14:17 -0500
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera Benzinga NewsdeskWed, 21 Oct 2020 06:09:03 -0500
12 Healthcare Stocks Moving In Thursday's Pre-Market Session Benzinga InsightsThu, 08 Oct 2020 07:08:49 -0500
The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street Shanthi RexalineThu, 08 Oct 2020 06:52:19 -0500
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $33 Benzinga NewsdeskFri, 18 Sep 2020 06:11:29 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera PRNewswire2 days ago
Protagonist Therapeutics Reports Granting of Inducement Award PRNewswire3 days ago
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020 PRNewswire4 days ago
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference PRNewswireNov 25, 2020
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference PRNewswireNov 11, 2020
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update PRNewswireNov 04, 2020
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting PRNewswireNov 04, 2020
Protagonist Therapeutics Reports Granting of Inducement Award PRNewswireOct 30, 2020
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen PRNewswireOct 29, 2020
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera PRNewswireOct 21, 2020
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Protagonist Therapeutics' lead program Fast Track'd for polycythemia vera Seeking Alpha2 days ago
Protagonist Janssen Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma Seeking AlphaNov 03, 2020
Protagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists program Seeking AlphaOct 30, 2020
NantKwest COVID-19 Candidate, And Other News: The Good, Bad And Ugly Of Biopharma Seeking AlphaOct 25, 2020
Protagonist Therapeutics's lead asset an Orphan Drug in Europe for a type of blood cancer Seeking AlphaOct 21, 2020
Why Protagonist Should Be On Your Radar After Latest Trial Update Seeking AlphaJun 25, 2020
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag ZacksJun 18, 2020
Why Did Protagonist Therapeutics (PTGX) Soar 83.7% Today? ZacksMay 08, 2020
Rtw Investments, Llc Buys Homology Medicines Inc, Relmada Therapeutics Inc, Avadel ... GuruFocusMar 19, 2020
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Lags Revenue Estimates ZacksMar 10, 2020
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2020	EST	Actual	Surprise
EPS:	Expected 2020-11-04
Rev:	Expected 2020-11-04

Q4 2020	EST	Actual	Surprise
EPS:	Expected 2021-03-09
Rev:	Expected 2021-03-09

Company Profile

Start Investing

The Best Online Stock Trading Brokers

Best Free Stock Trading Brokers

Best Forex Brokers

Best Futures Brokers

How to Invest in Real Estate

Best Day Trading Courses

Brokerage Center

Compare All Online Brokerages

+

+

Market Overview

Tickers

Articles

Keywords

Protagonist Therapeutics, Inc. PTGX:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Start Investing

Brokerage Center